\
&
Contact us
\
&
Contact us
Marie Sklodowska-Curie Actions (MSCA) is a programme for doctoral education and postdoctoral training. MSCA equips researchers with new knowledge and skills, including transferable ones and providing them with an international as well as inter-sectoral exposure (including through academia-business collaboration). MSCA also contribute to the development of excellent doctoral programmes, postdoctoral training programmes and collaborative research projects.
Main principles applying to MSCA
There are five Marie Sklodowska-Curie Actions:
margot.beereboom@fwo.be
+32 2 550 15 76
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
MSCA Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment
The 2026-2027 "Horizontal activities" Work Programme in Horizon Europe is created to break down the traditional walls between different scientific departments and funding silos. Rather than keeping research fragmented across separate categories, this new program pools resources to tackle the EU’s most urgent, evolving policy priorities i... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
